NeuroBo Pharmaceuticals, Inc. NRBO
At closeNov 27, 2024, 4:00 PM EST
52-week range unavailable
- Market cap
- 20.33M
- Shares out
- 8.62M
- Forward P/E
- -1.39
- Previous close
- 2.36
- Day's range
- 2.36 – 2.36
- Beta
- -0.28
- Analysts
- Strong Buy
- Price target
- 26.67 (+1029.9%)
- Earnings date
- Nov 7, 2024
Key statistics
- Enterprise value
- 437.95K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 21.67M
- Total debt
- 154.00K
- Return on equity
- -160.76%
- Short % of float
- 1.06%
- 50-day average
- 2.59
- 200-day average
- 3.63
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 26.67
- Target (high)
- 48.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 7, 2024
Expected Nov 7, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.82 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.38 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.95 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | -0.73 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2024 | Maxim Group | init | — | Buy |
About NeuroBo Pharmaceuticals, Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metaviatx.com
News
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases 
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November 
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update 
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH 
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October 
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity 
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update 
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity 
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
Your note
Sign in to keep a note on NRBO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 5,347,790 |
| GLICKMAN MARK A | Director | Stock Award(Grant) | Jun 6, 2024 | 9,740 |
| GROVES JASON L | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
| KIM HYUNG HEON | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 625,064 |
| KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 26, 2023 | 302,013 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.84% | 848,000 | 2.00M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 1.04% | 89,222 | 210.56K | Sep 29, 2024 |
| Vanguard Group Inc | 0.70% | 60,452 | 142.67K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.38% | 32,574 | 76.87K | Sep 29, 2024 |
| Ferguson Wellman Capital Management, Inc. | 0.18% | 15,670 | 36.98K | Sep 29, 2024 |
| State Street Corporation | 0.18% | 15,633 | 36.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.33% | 28,020 | 66.13K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 20,008 | 47.22K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.22% | 19,328 | 45.61K | Jun 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 4,864 | 11.48K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 4,667 | 11.01K | Sep 29, 2024 |
| DFA U.S. Small Cap Series | 0.00% | 355 | 837 | Jul 30, 2024 |